Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BCDA
$1.185
$
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Next Earnings
2026-02-25
Beta
0.609
Average Volume
Market Cap
Last Dividend
CIK
0000925741
ISIN
US09060U6064
CUSIP
09060U507
CEO
Peter A. Altman
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
17
IPO Date
1996-11-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart | SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter (“Helix”) for intramyocardial therapeutic and diagnostic agent delivery. | GlobeNewsWire | 2026-02-10 09:15:00 |
| BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA | SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on our CardiAMP Cell Therapy intended for treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The meeting was held in further preparation for formal clinical consultation on acceptability of the existing clinical data for submission of an application for approval. Based on the discussions in the most recent meeting, PMDA said it will allow BioCardia to advance to formal clinical consultation. Should PMDA agree in formal consultation that the available data provides sufficient evidence of safety and efficacy, BioCardia would be able to file for regulatory approval in Japan. | GlobeNewsWire | 2025-12-16 08:00:00 |
| BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress | SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia's President and Chief Executive Officer, Peter Altman, PhD, will make an invited presentation entitled, “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.” | GlobeNewsWire | 2025-12-01 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 8-K | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| S-8 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 3 | 2025-12-10 | 2025-12-10 | View Filing |
| 8-K | 2025-12-03 | 2025-12-03 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| DEF 14A | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-30 | 2025-10-30 | View Filing |
| 10-Q/A | 2025-10-29 | 2025-10-29 | View Filing |
| 424B5 | 2025-10-24 | 2025-10-24 | View Filing |
| 8-K | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-10-02 | 2025-10-02 | View Filing |
| SC 13G | 2025-09-24 | 2025-09-24 | View Filing |
| 8-K | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-23 | 2025-09-23 | View Filing |
| 4 | 2025-09-23 | 2025-09-23 | View Filing |
| 4 | 2025-09-23 | 2025-09-23 | View Filing |
| 8-K | 2025-09-22 | 2025-09-22 | View Filing |
| SC 13G | 2025-09-19 | 2025-09-19 | View Filing |
| 8-K | 2025-09-19 | 2025-09-19 | View Filing |
| 424B4 | 2025-09-19 | 2025-09-19 | View Filing |
| EFFECT | 2025-09-19 | 2025-09-19 | View Filing |
| 8-K | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-18 | 2025-09-18 | View Filing |
| S-1/A | 2025-09-17 | 2025-09-17 | View Filing |
| S-1 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 4 | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13G/A | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-08-12 | 2025-08-12 | View Filing |
| 4 | 2025-08-11 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| 8-K | 2025-07-24 | 2025-07-24 | View Filing |
| EFFECT | 2025-07-18 | 2025-07-18 | View Filing |
| EFFECT | 2025-07-18 | 2025-07-18 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| S-3 | 2025-07-09 | 2025-07-09 | View Filing |
| 424B5 | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-06-25 | 2025-06-25 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| SC 13D | 2025-05-22 | 2025-05-22 | View Filing |
| SC 13D/A | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| 8-K | 2025-05-01 | 2025-05-01 | View Filing |
| S-3 | 2025-04-30 | 2025-04-30 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| 4 | 2025-04-17 | 2025-04-17 | View Filing |
| 8-K | 2025-04-15 | 2025-04-15 | View Filing |
| 4 | 2025-04-14 | 2025-04-14 | View Filing |
| 8-K | 2025-04-11 | 2025-04-11 | View Filing |
| 4 | 2025-04-08 | 2025-04-08 | View Filing |
| 4 | 2025-04-07 | 2025-04-07 | View Filing |
| 4 | 2025-04-04 | 2025-04-04 | View Filing |
| 424B5 | 2025-04-04 | 2025-04-04 | View Filing |
| 8-K | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| S-8 | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-02-27 | 2025-02-27 | View Filing |
| 8-K | 2025-02-13 | 2025-02-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 64.89% | 1 | 692 | 0.04 | 0.09 | 53.47 |
| Quantum Inspired Strategy | 51.42% | 1.01 | 343 | 0.03 | 0.06 | 40 |
| Choppiness Index Strategy | 46.33% | 0.99 | 575 | 0.04 | 0.09 | 34.91 |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |